secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0000886163-24-000061
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand completes acquisition of APEIRON Biologics for $100M cash plus up to $28M contingent
--------------------------------------------------------------------------------

- Ligand acquired all outstanding shares of APEIRON for $100M in cash at closing on July 15, 2024.
- Additional contingent consideration up to $28M if QARZIBA royalties exceed predetermined thresholds by 2030 or 2034.
- QARZIBA (dinutuximab beta) is approved for high-risk neuroblastoma; Ligand obtains royalty rights.
- Acquisition funded from Ligand's available cash on hand; closing subject to 30-day shareholder objection period.
- Deal structured as a definitive agreement first announced on July 8, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/0000886163-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/lgnd-20240715.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer